BioSpace News Archive

Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine, Inc. (collectively “Clene”), today announced long-term follow-up data for patients treated with CNM-Au8 30mg for up to 133 weeks in the HEALEY ALS Platform Trial.

CytoMed Therapeutics Limited today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).

ProFound™ Therapeutics today announced the appointment of Klaus Urbahns, Ph.D., as Chief Scientific Officer.

Aviceda Therapeutics announced today multiple upcoming presentations about its lead ophthalmic clinical asset, AVD-104.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J2781) for SYFOVRE ® (pegcetacoplan injection), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration.

Kintara Therapeutics, Inc. today announced the presentation of compelling patient case studies in a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting in Rotterdam.

Zucara Therapeutics Inc., today announced that it has dosed the first patient in its Phase 2a trial of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes (“T1D”) mellitus (“ZONE”).

MMI, a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, announced the successful completion of over 500 in-human surgeries with the Symani® Surgical System in the European Union.

Genmab A/S announced that the European Commission has granted conditional marketing authorization for TEPKINLY® as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

Appili Therapeutics Inc. today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) received approval from the U.S. Food and Drug Administration (“FDA”) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501).